Closure of ATP-sensitive potassium channels in pancreatic islet β-cells initiates a cascade of events that leads to insulin secretion. β-Cell ATP-sensitive potassium currents can be reconstituted by coexpression of the inward rectifier Kir6.2 and the sulfonylurea receptor (SUR), a member of the ATP-binding cassette superfamily. Mutations in SUR have been identified in individuals affected with familial persistent hyperinsulinemic hypoglycemia of infancy (PHHI), an autosomal recessive disorder of glucose metabolism which is linked to chromosome 11p15.1 and characterized by unregulated secretion of insulin and profound hypoglycemia. Because the Kir6.2 locus is within 5 kilobases (kb) of the SUR gene on chromosome 11p15.1 and it is a necessary member of the β-cell K ATP channel, we considered Kir6.2 as a candidate gene for PHHI. We identified a homozygous point mutation in Kir6.2 in the genomic DNA of a child, severely affected with PHHI, from a consanguineous family. This mutation is predicted to disrupt the conserved α-helical second transmembrane (M2) domain of the inward rectifier by substitution of a proline for a leucine residue (L147P). Mutation of Kir6.2, like SUR, appears to lead to the PHHI phenotype suggesting that Kir6.2 is necessary, although not sufficient, for normal regulation of insulin release.
INTRODUCTION
Persistent hyperinsulinemic hypoglycemia of infancy (PHHI) is characterized by profound hypoglycemia due to unregulated secretion of insulin (1) . Inheritance is in an autosomal recessive pattern, and linkage to chromosome 11p15.1 has been established (2, 3) . Subsequently, mutations in the first and second nucleotide binding folds of the sulfonylurea receptor (SUR) gene, a subunit of the pancreatic-islet β-cell ATP-sensitive potassium (K ATP ) channel have been identified as causative for PHHI in some families (4, 5) .
The resting membrane potential of pancreatic islet β-cells is set by K ATP channels. As a result of glucose metabolism, alterations in the intracellular ATP/ADP ratio inhibit β-cell ATP-sensitive potassium currents (I KATP ) and ultimately result in an increase in exocytosis of insulin (6) thereby creating a link between the metabolic state of the cell and membrane electrical events. Reconstitution of I KATP requires the presence of the inward rectifier Kir6.2 in addition to the SUR (7). Kir6.2 has been mapped to chromosome 11p15.1, ∼5 kb from SUR. We hypothesized that familial PHHI could also result from inactivation of Kir6.2.
RESULTS

Description of Kir6.2 L147P missense mutation
Genomic DNA samples from members of 15 families affected with PHHI were evaluated. To assess whether mutation of Kir6.2 was present, screening was performed using the RNase cleavage assay (MisMatch Detect™ II, Ambion Inc., Austin, TX). Since Kir6.2 lacks introns within its coding region and this sequence is <1.5 kb in length (7), we were able to use genomic DNA as a template for polymerase chain reaction (PCR) amplification of a single product for screening the coding sequence.
The affected child of family 21 was of Mid-Eastern (Iranian) origin and the progeny of a first cousin mating. Profound hypoglycemia presented within hours of birth. The diagnosis of PHHI was made by one of us (E.L.) using established criteria (1), which included an insulin level of >30 µU/ml with a simultaneous glucose determination of <30 mg/ dl, and glucose requirements of >15 mg/kg/min to maintain euglycemia. Hypoglycemia persisted despite medical therapy with diazoxide, glucagon and somatostatin. Subsequently, a sub-total pancreatectomy (95%) was performed. Histopathological examination of the operative specimen revealed diffuse nesidioblastosis.
Sequence analysis of 18 exons of SUR, including those coding for both nucleotide-binding folds, revealed wild-type sequence in this affected individual (data not shown), prompting the search for a mutation in Kir6.2. Analysis of samples from this affected individual for mutation of Kir6.2 revealed a cleavage pattern different from the wild-type pattern, and that Kir6.2 amplicon was cloned and sequenced. A homozygous T!C point mutation was found at nucleic acid residue 649 of the genomic sequence (7) (Fig. 1) , which would result in a proline substitution at residue 147 (L147P) of Kir6.2. This individual is the product of a consanguineous mating and, therefore, is expected to be homozygous by descent at the disease gene locus (8) . The only other change found in the remainder *To whom correspondence should be addressed The 188 bp wild-type PCR product is not digested, whereas that containing the C point mutation was digested into 170 and 18 bp fragments. The 18 bp fragment has been run off this gel. MW, molecular weight markers from a 100 bp ladder (Gibco BRL); PU and NU, patient and normal uncut samples; NC, normal control cut with PvuI; Bl, control PCR reaction lacking template. of the Kir6.2 sequence in this individual was a T at nucleic acid position 652 instead of the G indicated in the published sequence (7) (Fig. 1) . This change was also found in all 27 additional control and affected individuals evaluated (see below).
The presence of the point mutation allowed an engineered PvuI restriction endonuclease recognition site to be created (see Materials and Methods) providing a means to confirm and test for the presence of the mutation. The affected child was homozygous, whereas the parents were heterozygous for the mutation (Fig. 2) . Analysis using marker D11S902, which is located within 1 cM of the SUR gene (9), supported that the affected individual was homozygous and the parents heterozygous in this region (data not shown). Restriction digestion of all PCR products prepared from the genomic DNA of 50 unrelated control individuals, of which 18 were of Mid-Eastern origin, and 32 of mixed ethnic origin, showed the normal PvuI restriction pattern.
Description of sequence variants
While searching for mutations in Kir6.2 we consistently found a T at nucleic acid position 652 instead of the G indicated in the published sequence (7) (Fig. 1) . This substitution introduced an AlwI restriction endonuclease recognition site. Analysis of 13 normal controls and 14 affected individuals of diverse genetic background, by either direct sequence analysis or AlwI digestion of PCR amplified products, revealed that all were homozygous for the T residue, suggesting that the published sequence was in error. This T!G substitution changes amino acid 148 from a serine to an isoleucine residue, which is in agreement with that found in the mouse Kir6.2 sequence at this position (7) . Three additional sequence variants were found, including E23K in five affected families (frequency in 26 normal chromosomes 50%), A190t!c in five affected families and L339V in three affected families. No correlation between genotype and phenotype could be established in those families exhibiting these variations.
DISCUSSION
We discovered a Kir6.2 gene mutation in an affected individual with severe familial PHHI demonstrating genetic heterogeneity for this disorder. No phenotypic difference is discernable between this family and those with mutations of the first or second nucleotide binding fold regions of SUR (P.M.Thomas, unpublished data). Interestingly, in rats Kir6.2 mRNA has been shown to be expressed in heart and brain (10) , however, no discernable abnormalities were present in those systems in this patient.
The inward rectifier K + channels are found in a variety of cell types where they allow K + influx, but little K + outflux, from the cell. They, therefore, have a significant role in the maintenance of the resting potential of the cell (11) . This family of proteins characteristically contains two predicted α-helical transmembrane spanning domains (M1 and M2) (11) (12) (13) , which correspond to transmembrane regions S5 and S6 of voltage-gated K + channels (14, 15) . The hydrophobic domain, comprised of M1, M2, and the intervening sequence H5 as well as the hydrophilic C-terminal domain, have been implicated as the major part of the ion channel pore (11, 12, 16, 17) . The presence of a proline substitution within the M2 region of Kir6.2 is predicted to result in disruption of this α-helical domain (18, 19) . Alignment of Kir6.2 with other members of the inward rectifier family revealed the presence of hydrophobic residues, and the absence of proline residues, in the M2 domain. Insertion of proline residues within transmembrane domains of other proteins, including the V2 vasopressin receptor, have been demonstrated to lead to loss of function (20) .
I KATP functions in pancreatic islet β-cells to link the metabolic state of the cell with membrane electrical events. When expressed individually neither Kir6.2 nor SUR produces I KATP (7, 21) . SUR has been shown to couple to several inward rectifier channels conferring sulfonylurea sensitivity upon them (21) , and other inward rectifiers are expressed in the pancreas (22, 23) , raising the possibility that a combination different from SUR and Kir6.2 may be responsible for the β-cell I KATP . However, demonstration that loss of function of either Kir6.2 or SUR leads to unregulated secretion of insulin and the PHHI phenotype, supports the model that these two subunits cooperate in the formation of I KATP . Detailed functional studies involving the L147P mutant form of Kir6.2, in combination with SUR, are required to confirm the effect of this mutation on I KATP .
Sulfonylurea drugs are used to elevate levels of insulin secretion, through inhibition of pancreatic islet β-cell K ATP channels, in the therapy of non-insulin dependent diabetes mellitua (24) . Primary and secondary failures of sulfonylurea treatment frequently occur (25) . The effects of sulfonylureas are not limited to the pancreas and adverse extrapancreatic effects have been described (24) . The demonstration that mutation of Kir6.2 also leads to the PHHI phenotype may provide it as another target for control of insulin release. Whether additional mutations of Kir6.2 will be found to be correlated with PHHI or other more heterogeneous disorders of insulin secretion, including some forms of diabetes mellitus, remains to be determined.
MATERIALS AND METHODS
Leukocyte DNA was obtained from peripheral blood samples according to the manufacturer's direction (Qiagen, Chatsworth, CA). Oligonucleotide primers were based on the published sequence (7). Kir6.2 coding sequence was amplified using primers 207 (5′-CTAGGCCACGTCCGAGG) and 208 (5′-ATG-GTCCGTGTGTACA) in a 50 µl PCR amplification reaction containing ∼100-200 ng of genomic DNA, 250 µM of each dNTP, 2. Amplified products were either directly sequenced, as previously described (26) , or cloned (TA Cloning Kit, Invitrogen, La Jolla, CA) and sequenced using a fluorescent sequencing protocol (Applied Biosystems). Sequencing primer 202 (5′-CTCATCGCCTTCGCC-CAC) was used to detect the described mutation.
In order to test for the mutation, a PvuI restriction endonuclease digestion site (CGAT/CG) was introduced into the mutant sequence by PCR amplification of genomic DNA using PCR conditions as described above (with the exception that the PCR buffer was at pH 9.5), primer 202 and the modified downstream primer 210 (5′-TGTTCTGCACGATGACGATC). In the wild-type sequence, the nucleic acid at position 16 of primer 210, presented here in bold, is a G residue. One fifth of the PCR amplification reaction was digested with 5 U PvuI enzyme for 2 h and separated by electrophoresis on a 12% polyacrylamide gel.
To test the identity of base 652, either direct sequence analysis or restriction digestion with the endonuclease AlwI was performed on the 462 bp PCR amplicon obtained with primer 202 and 203 (5′-ACCCACGCCGTTCTCCAT), using the conditions and methods described above.
